Table of Content


1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Respiratory Pipeline
4 Market Outlook
4.1 Product Pipeline
4.2 Market Segmentation
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising prevalence of cystic fibrosis diseases
5.1.1.2 Advancements in screening and treatments technology
5.1.1.3 High prevalence of tobacco smoking
5.1.2 Restraints
5.1.2.1 Complex drug development process
5.1.2.2 Expensive treatment options for cystic fibrosis
5.1.3 Opportunities
5.1.3.1 Initiatives from government and other organization
5.1.3.2 Promising pipeline for the treatment of cystic fibrosis
5.1.3.3 Market expansion opportunities in emerging nations
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Drug Class: Market Size and Analysis
6.1 Overview
6.2 CFTR Modulators
6.3 Mucolytics
6.4 Bronchodialators
6.5 Pancreatic Enzyme Supplements
6.6 Others
7 Route of Administration: Market Size and Analysis
7.1 Overview
7.2 Oral 7.3 Inhalation
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 Overview 37

8.3 Europe
8.3.1 Overview

8.4 Asia Pacific
8.4.1 Overview
8.5 Rest of the World
8.5.1 Overview
9 Competitive Landscape 48
10 Vendors Profile 50
10.1 AbbVie 50
10.2 F. Hoffmann-La Roche 52
10.3 Gilead Sciences, Inc. 54
10.4 Vertex Pharmaceuticals 57
10.5 Novartis 60
11 Companies to Watch for 64
11.1 Advanced Inhalation Therapies (AIT) Ltd. 64
11.2 Alcresta Therapeutics, Inc. 65
11.3 Allergan Plc 66
11.4 AstraZeneca 67
11.5 Merck & Co. Inc 68
11.6 PharmaSwiss 69
Annexure 71
? Acronyms 71

?



List of Figures



Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL CYSTIC FIBROSIS DRUGS MARKET
CHART 2 CYSTIC FIBROSIS DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 3 CYSTIC FIBROSIS DRUGS MARKET SEGMENTATION
CHART 4 PORTERS 5 FORCES ON CYSTIC FIBROSIS DRUGS MARKET
CHART 5 PEST ANALYSIS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 6 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
CHART 7 DRO - IMPACT ANALYSIS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 8 KEY STAKEHOLDERS OF CYSTIC FIBROSIS DRUGS MARKET
CHART 9 CYSTIC FIBROSIS DRUGS MARKET SEGMENT REVENUE, BY DRUG CLASS, 2018 ($MILLION)
CHART 10 CFTR MODULATORS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 11 MUCOLYTICS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 12 BRONCHODIALATORS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 13 PANCREATIC ENZYME SUPPLEMENTS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 14 OTHERS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
CHART 15 CYSTIC FIBROSIS DRUGS MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
CHART 16 ORAL MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)CHART 17 INHALATION MARKET SEGMENT REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
CHART 18 CYSTIC FIBROSIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2018 (%)
CHART 19 CYSTIC FIBROSIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2025 (%)
CHART 20 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION)
CHART 21 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION)
CHART 22 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION)
CHART 23 CYSTIC FIBROSIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION)
 

 

List of Tables



Tables

TABLE 1 CYSTIC FIBROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2018–2025 ($MILLION)
TABLE 2 CYSTIC FIBROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2025 ($MILLION)
TABLE 3 CYSTIC FIBROSIS DRUGS REVENUE, BY GEOGRAPHY, 2018–2025 ($MILLION)
TABLE 4 BUSINESS SUMMARY: ABBVIE
TABLE 5 BUSINESS SUMMARY: F. HOFFMANN-LA ROCHE
TABLE 6 BUSINESS SUMMARY: GILEAD SCIENCES, INC
TABLE 7 BUSINESS SUMMARY: VERTEX PHARMACEUTICALS
TABLE 8 BUSINESS SUMMARY: NOVARTIS
TABLE 9 BUSINESS SUMMARY: ADVANCED INHALATION THERAPIES (AIT) LTD.
TABLE 10 BUSINESS SUMMARY: ALCRESTA THERAPEUTICS INC
TABLE 11 BUSINESS SUMMARY: ALLERGAN PLC
TABLE 12 BUSINESS SUMMARY: ASTRAZENECA
TABLE 13 BUSINESS SUMMARY: MERCK & CO. INC
TABLE 14 BUSINESS SUMMARY: PHARMASWISS

?